A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions
Part of paid clinical trials in Indianapolis, Indiana.
- Sponsor
- Amplified Sciences Inc
- Study ID
- NCT06894329
- Status
- Recruiting
Conditions
- Pancreatic Cystic Lesions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test reports if the cyst fluid should be considered "Non-mucinous" or "Mucinous". Mucinous pancreatic cysts are more likely to progress to cancer while non-mucinous cysts seldom progress to cancer.
Key Dates
- Start date
- Feb 17, 2026
- Status verified
- Mar 2026
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 50 participants (estimated)
Primary Outcome Measure
The percentage of subjects for which the providers indicated positive impact of the PanCystPro assay. [ Time Frame: 1 month. ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Indiana University | Indianapolis | Indiana | 46202 | |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | |
| Rutgers Health | New Brunswick | New Jersey | 08901 |
Find similar trials in Indianapolis, IN
Related Studies
- A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst LesionsRecruiting · The University of Texas Health Science Center, Houston · Houston, Texas